Stock Scorecard
Stock Summary for Novo Nordisk (NVO) - $58.74 as of 10/3/2025 3:13:13 PM EST
Total Score
15 out of 30
Safety Score
73 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for NVO
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for NVO
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for NVO
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for NVO
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for NVO (73 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 9 |
| Stock Price Trend (Max of 10) | 9 |
| Book Value (Max of 10) | 8 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 4 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 6 |
| Operating Margin (Max of 10) | 6 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 9 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for NVO
Financial Details for NVO
Company Overview |
|
|---|---|
| Ticker | NVO |
| Company Name | Novo Nordisk |
| Country | USA |
| Description | Novo Nordisk A/S is a leading global healthcare company based in Bagsvaerd, Denmark, specializing in the development and manufacturing of pharmaceuticals, particularly in the fields of diabetes care, obesity treatment, and hormone replacement therapy. With a strong focus on innovation and sustainability, Novo Nordisk leverages advanced biotechnology and scientific research to deliver effective solutions for chronic diseases. As a key player in the biopharmaceutical industry, the company is committed to improving patient outcomes while maintaining responsible business practices. |
| Sector Name | HEALTHCARE |
| Industry Name | DRUG MANUFACTURERS - GENERAL |
| Most Recent Quarter | 6/30/2025 |
| Next Earnings Date | 11/5/2025 |
Stock Price History |
|
| Last Day Price | 58.74 |
| Price 4 Years Ago | 52.46 |
| Last Day Price Updated | 10/3/2025 3:13:13 PM EST |
| Last Day Volume | 15,300,706 |
| Average Daily Volume | 14,638,551 |
| 52-Week High | 117.32 |
| 52-Week Low | 44.54 |
| Last Price to 52 Week Low | 31.88% |
Valuation Measures |
|
| Trailing PE | 14.98 |
| Industry PE | 26.58 |
| Sector PE | 41.81 |
| 5-Year Average PE | 23.21 |
| Free Cash Flow Ratio | 10.74 |
| Industry Free Cash Flow Ratio | 38.57 |
| Sector Free Cash Flow Ratio | 30.43 |
| Current Ratio Most Recent Quarter | 0.78 |
| Total Cash Per Share | 5.47 |
| Book Value Per Share Most Recent Quarter | 37.82 |
| Price to Book Ratio | 9.88 |
| Industry Price to Book Ratio | 10.68 |
| Sector Price to Book Ratio | 32.30 |
| Price to Sales Ratio Twelve Trailing Months | 0.83 |
| Industry Price to Sales Ratio Twelve Trailing Months | 3.95 |
| Sector Price to Sales Ratio Twelve Trailing Months | 20.26 |
| Analyst Buy Ratings | 4 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 3,368,558,000 |
| Market Capitalization | 197,869,096,920 |
| Institutional Ownership | 9.35% |
Dividends |
|
| Ex-Dividend Date | 8/18/2025 |
| Previous Dividend Amount | 1.1426 |
| Current Dividend Amount | 0.5843 |
| Total Years Dividend Increasing | 0 |
| Trailing Annual Dividend Rate | 1.73 |
| Trailing Annual Dividend Yield | 2.94% |
| Forward Annual Dividend Rate | 1.17 |
| Forward Annual Dividend Yield | 1.99% |
| 5-Year Dividend Payments Count | 10 |
| 3-Year Average Dividend Yield | 1.38% |
| 5-Year Average Dividend Yield | 1.35% |
| 1-Year Dividend Growth Rate Percentage | 19.36% |
| 3-Year Dividend Growth Rate Percentage | 29.35% |
| 5-Year Dividend Growth Rate Percentage | 23.76% |
| All-Time Dividend Growth Rate Percentage | 10.45% |
| Dividend Payout Ratio | 44.05% |
Income Statement |
|
| Quarterly Earnings Growth YOY | 32.70% |
| Annual Earnings Growth | 20.68% |
| Reported EPS 12 Trailing Months | 3.92 |
| Reported EPS Past Year | 12.49 |
| Reported EPS Prior Year | 13.95 |
| Net Income Twelve Trailing Months | 111,068,000,000 |
| Net Income Past Year | 100,988,000,000 |
| Net Income Prior Year | 83,683,000,000 |
| Quarterly Revenue Growth YOY | 12.90% |
| 5-Year Revenue Growth | 18.94% |
| Operating Margin Twelve Trailing Months | 43.50% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 18,435,000,000 |
| Total Cash Past Year | 15,655,000,000 |
| Total Cash Prior Year | 14,392,000,000 |
| Net Cash Position Most Recent Quarter | -68,870,000,000 |
| Net Cash Position Past Year | -68,591,000,000 |
| Long Term Debt Past Year | 84,246,000,000 |
| Long Term Debt Prior Year | 15,976,000,000 |
| Total Debt Most Recent Quarter | 87,305,000,000 |
| Equity to Debt Ratio Past Year | 0.63 |
| Equity to Debt Ratio Most Recent Quarter | 0.66 |
| Total Stockholder Equity Past Year | 143,486,000,000 |
| Total Stockholder Equity Prior Year | 106,561,000,000 |
| Total Stockholder Equity Most Recent Quarter | 168,066,000,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 61,989,000,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 18.40 |
| Free Cash Flow Past Year | 69,659,000,000 |
| Free Cash Flow Prior Year | 70,012,000,000 |
Options |
|
| Put/Call Ratio | 0.40 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.00 |
| MACD Signal | 0.00 |
| 20-Day Bollinger Lower Band | 0.00 |
| 20-Day Bollinger Middle Band | 0.00 |
| 20-Day Bollinger Upper Band | 0.00 |
| Beta | 0.33 |
| RSI | 0.00 |
| 50-Day SMA | 0.00 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 10/4/2025 5:49:44 AM EST |